In a release, the Company noted that the tender offer expired at 12 midnight ET, at the end of September 4. At that time, the depositary for the offer advised Covidien that 15,210,583 shares of PMI had been validly tendered and not withdrawn, representing approximately 87 percent of the outstanding PMI common shares. All shares that were validly tendered and not withdrawn were accepted for purchase and paid for in accordance with the tender offer. An additional 247,765 shares, or approximately 1.4 percent of the outstanding PMI shares, had been tendered pursuant to notices of guaranteed delivery.
Pursuant to the terms of the merger agreement, Covidien Delaware Corp., a subsidiary of Covidien, exercised its option to purchase newly issued shares from PMI at the tender offer price. This permitted Covidien Delaware Corp. to acquire sufficient shares to effect a short-form merger with and into PMI, which then became a subsidiary of Covidien.
"The acquisition of Power Medical will expand our stapling product line and is consistent with our strategy to deliver innovative healthcare solutions that enable advanced surgical care," said Scott Flora, President, Surgical Devices, Covidien. "As a pioneer in surgical stapling, we are committed to advancing healthcare technology to improve patient outcomes."
((Comments on this story may be sent to health@closeupmedia.com))

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index